An Open-label Phase II Study of Two Dose Levels of EMD 273066 Administered With Low-dose Cyclophosphamide Following Objective Response to Second-line Chemotherapy in Women With Recurrent Ovarian Carcinoma.

Trial Profile

An Open-label Phase II Study of Two Dose Levels of EMD 273066 Administered With Low-dose Cyclophosphamide Following Objective Response to Second-line Chemotherapy in Women With Recurrent Ovarian Carcinoma.

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 21 Aug 2017

At a glance

  • Drugs Tucotuzumab celmoleukin (Primary) ; Cyclophosphamide
  • Indications Ovarian cancer
  • Focus Therapeutic Use
  • Sponsors EMD Serono
  • Most Recent Events

    • 15 Aug 2017 Status changed from discontinued to withdrawn prior to enrolment.
    • 05 Nov 2010 Actual end date (Jun 2007) added as reported by ClinicalTrials.gov.
    • 05 Nov 2010 Actual initiation date (Dec 2006) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top